In addition, the WHO uses a blast threshold of 20% to define AML transformation from MDS in the category of MDS with biallelic TP53 inactivation (albeit with a note that MDS with increased blast-2 (≥10% blasts) may be regarded as “AML-equivalent” for therapy and clinical trials enrollment, when appropriate). Here, TP53 is linked to acute myeloid leukemia.